A presentation chronic prostate inflammation symptom progression and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients. They presented the results of a 4 year longitudinal association between histological prostate inflammation in men with a negative prostate biopsy and who have a diagnosis of chronic prostatitis/chronic pelvis pain (REDUCE study).
Patients were randomized to drug or placebo to determine whether 0.5 mg Dutasteride daily decreased the risk of biopsy detectable prostate cancer. Acute and chronic inflammation was detected in 641 men (15.6%) and 3216 (78.3%) of the 4109 men in the study. A total of 98.3% of men did not have a history baseline CP/CPPS. The authors concluded that histologic inflammation and negative prostate biopsies are not associated with an increased risk of developing chronic pain but that chronic inflammation does predict increased risk of symptomatic progression in men who have identified CP/CPPS symptoms at baseline prior to prostate needle biopsy.
Presented by: J. Curtis Nickel, et al. American Urological Association (AUA) Annual Meeting Saturday, May 7, 2016 at San Diego, CA
Diane K. Newman, DNP, Adjunct Professor of Urology in Surgery, Research Investigator Senior and Co-Director, Penn Center for Continence and Pelvic Health
University of Pennsylvania, Division of Urology, 3400 Spruce Street, 3rd Floor Perelman Bldg, Philadelphia, PA. 19104